Jean Jacques Bienaime - 11 May 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
11 May 2023
Net transactions value
-$805,926
Form type
4
Filing time
15 May 2023, 16:58:53 UTC
Previous filing
11 May 2023
Next filing
16 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $2,034,300 +30,000 +7% $67.81 456,213 11 May 2023 Direct F1
transaction BMRN Common Stock Sale $2,310,707 -24,439 -5.4% $94.55 431,774 11 May 2023 Direct F1, F2
transaction BMRN Common Stock Sale $529,518 -5,561 -1.3% $95.22 426,213 11 May 2023 Direct F1, F3
holding BMRN Common Stock 247,333 11 May 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 11 May 2023 Shares held as UTMA custodian for child
holding BMRN Common Stock 100 11 May 2023 Shares held as UTMA custodian for child

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -30,000 -43% $0.000000 39,130 11 May 2023 Common Stock 30,000 $67.81 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
F2 The price in column 4 is the weighted average price. The price actually received ranged from $93.935 to $94.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F3 The price in column 4 is the weighted average price. The price actually received ranged from $94.94 to $95.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4 Reflects the number of options outstanding after the transactions from this specific stock option grant.